These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab. Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767 [No Abstract] [Full Text] [Related]
7. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma. Sato M; Uhara H; Koga H; Okuyama R J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228 [No Abstract] [Full Text] [Related]
12. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma. Koksal AS; Toka B; Eminler AT; Hacibekiroglu I; Uslan MI; Parlak E Ann Oncol; 2017 Dec; 28(12):3103-3104. PubMed ID: 28945827 [No Abstract] [Full Text] [Related]
13. Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient. Mandalà M; Merelli B; Indriolo A; Tondini C Eur J Cancer; 2018 May; 95():130-132. PubMed ID: 29559189 [No Abstract] [Full Text] [Related]
14. Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis. Yang Y; Pei J; Gao G; Yang Z; Guo S; Yue B; Qiu J Oncotarget; 2016 Dec; 7(49):80855-80871. PubMed ID: 27764796 [TBL] [Abstract][Full Text] [Related]
15. A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab. Oishi K; Nakao M; Maeda S; Matsushita T; Ikeda T; Yamada T; Takehara K; Hamaguchi Y Eur J Dermatol; 2017 Apr; 27(2):193-194. PubMed ID: 28007669 [No Abstract] [Full Text] [Related]
16. Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. van den Brom RR; Abdulahad WH; Rutgers A; Kroesen BJ; Roozendaal C; de Groot DJ; Schröder CP; Hospers GA; Brouwer E Rheumatology (Oxford); 2016 Jun; 55(6):1143-5. PubMed ID: 27069016 [No Abstract] [Full Text] [Related]
17. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab. Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534 [No Abstract] [Full Text] [Related]
18. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab. Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688 [TBL] [Abstract][Full Text] [Related]
19. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387 [TBL] [Abstract][Full Text] [Related]
20. [Immune checkpoint inhibitors and endocrinological side effects]. Jørgensen LB; Bastholt L; Yderstræde K Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]